Indicated for: cancer
Route of administration: oral
Substance: thioguanine (antineoplastic agent)
ATC: L01BB03 (Antineoplastic and immunomodulating agents | Antimetabolites | Purine analogues)
Thioguanine is an antimetabolite agent used in the treatment of acute leukemia and other hematologic cancers. It works by interfering with DNA and RNA synthesis in cancer cells, thereby inhibiting their growth and division.
The medication is taken orally, usually once daily, as directed by a doctor. The dosage is adjusted based on the patient's weight, clinical condition, and response to treatment.
Patients should be closely monitored to detect potential side effects, such as bone marrow suppression, nausea, or liver toxicity. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include nausea, vomiting, decreased blood cell counts, and elevated liver enzymes. In rare cases, severe reactions such as hepatotoxicity or serious infections may occur. Patients should be informed of these risks before starting treatment.